The drug, geranylgeranyltransferase inhibitor GGTI-2418 suppresses a new defective PTEN cancer pathway, researchers have discovered. A collaboration between Saïd M. Sebti, Ph.D., chair of Moffitt ...
PTEN, a tumor suppressor gene mutated in about 20% of prostate cancers, relies on another gene, ARID4B, to function. PTEN, a tumor suppressor gene mutated in approximately 20% of primary prostate ...
A collaboration between Saïd M. Sebti, Ph.D., chair of Moffitt Cancer Center's Drug Discovery Department, and Michele Pagano, M.D., chair of the Department of Biochemistry and Molecular Pharmacology ...
A means of determining whether the loss of the tumor suppressor gene PTEN predicts lethal outcomes in patients has been determined by a team from the Dana-Farber Cancer Institute. Using quantitative ...
In recent years, high-throughput technologies have provided unprecedented opportunities for analyzing cancer samples at multiple molecular levels. Each type of multi-omics dataset contributes to the ...
These are tumors generated from normal breast cells and from breast cells in which PTEN has been deleted. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback